We are approaching an ´post-antibiotic era´ where antibiotics will have much decreased efficacy, and antiseptics are not desirable due to side-effects, resistance, or toxicity. Therefore, the new drugs developed by in2cure AB are of high relevance and clinical need. The global wound care market is estimated is forecasted at $26-30 billion by 2018. The unique capacities of BioCure gel will enable us to address a significant portion of the market for advanced formulation and hydrogels.
Menu